InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Unique System That Rebuilds Human Airway on Relentless Dentist Podcast
June 9, 2021

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Unique System That Rebuilds Human Airway on Relentless Dentist Podcast

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), was featured in a recent episode of the Relentless Dentist podcast. The program features interviews with thought-provoking guests offering words of wisdom to help dentists gain the courage to develop the practices and lives of their dreams. Vivos Therapeutics CEO R. Kirk Huntsman joined the broadcast, hosted by certified High Performance Coach Dr. David Maloley, to discuss his professional background, his introduction to the company’s game-changing Vivos System(R), and his efforts to commercialize the platform for the treatment of sleep-disordered breathing. “Vivos has spent the last four years, literally since late 2016, building infrastructure, and the model is working,” Huntsman said. “Our Vivos-trained independent dentists have treated close to 17,000 patients with [the Vivos System]. … Mandibular advancement was never intended to be a lifelong solution to this problem. It was intended to be palliative and temporary, but neither the medical profession nor the dental profession has any good solution for sleep apnea. … With mandibular advancement and CPAP, the underlying condition gets worse over time. … That’s not true with Vivos. What the Vivos System does that’s unique is we actually rebuild the human airway. The treatment protocol repositions the jaws forward, making the dental arches wider, and they’re doing that in a stable manner.”

To view the full press release, visit https://ibn.fm/Cg9jH

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 17,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).